OABI
HEALTHCAREOmniAb Inc
Live · NASDAQ · May 9, Close
What's Moving OABI Today?
No stock-specific AI insight has been generated for OABI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.43
Fundamentals
Trading
OABI News
20 articles- OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 8, 2026
- OmniAb Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 7, 2026
- OmniAb to Participate in Three Upcoming Investor ConferencesYahoo Finance·Apr 24, 2026
- Bullish OmniAb Insiders Loaded Up On US$1.28m Of StockYahoo Finance·Apr 22, 2026
- OmniAb to Report First Quarter 2026 Financial Results on May 7Yahoo Finance·Apr 21, 2026
- OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026Yahoo Finance·Apr 14, 2026
- Here Is Why You Should Not Ignore OmniAb Inc. (OABI)Yahoo Finance·Mar 31, 2026
- OmniAb (OABI) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 15, 2026
- OmniAb, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 5, 2026
- OmniAb Inc (OABI) Q4 2025 Earnings Call Highlights: Strong Partner Engagement and New ...Yahoo Finance·Mar 5, 2026
- OmniAb Q4 Earnings Call HighlightsMarketbeat·Mar 5, 2026
- OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 4, 2026
- OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsYahoo Finance·Mar 4, 2026
- OmniAb to Participate at the Leerink Partners Global Healthcare ConferenceYahoo Finance·Feb 24, 2026
- OmniAb to Report Fourth Quarter 2025 Financial Results on March 4Yahoo Finance·Feb 19, 2026
- OmniAb, Inc. (NASDAQ:OABI) has caught the attention of institutional investors who hold a sizeable 36% stakeYahoo Finance·Jan 6, 2026
- Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery TechnologiesYahoo Finance·Dec 15, 2025
- Here's Why We're Not Too Worried About OmniAb's (NASDAQ:OABI) Cash Burn SituationYahoo Finance·Dec 10, 2025
- OmniAb to Hold OmniUltra Virtual Investor Event on December 15Yahoo Finance·Dec 4, 2025
- OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global InvestorsYahoo Finance·Nov 17, 2025
All 20 articles loaded
Price Data
52-Week Range
$1.43
Fundamentals
Trading
About OmniAb Inc
OmniAb Inc. is a pioneering biotechnology firm focused on the creation of fully human therapeutic antibodies through its cutting-edge OmniAb platform. This unique technology facilitates the rapid discovery and refinement of high-efficacy therapeutics to tackle a diverse range of diseases. By fostering strategic partnerships and collaborations, OmniAb strives to expedite drug development and broaden access to innovative therapies. With an experienced leadership team and a strong product pipeline, the company is well-positioned to seize expanding opportunities within the biopharmaceutical landscape.